David Amsellem

Marc Goodman

Paul Matteis

Umer Raffat

Uy Ear

Charles Duncan

Douglas Tsao

Jason Gerberry

Jessica Fye

Joel Beatty

Joseph Thome

Ashwani Verma

David Hoang

Leonid Timashev

Adam Ferrari

Akash Tewari

Akash Tiwari

Ami Fadia

Anastasia Parafestas

Andrea Newkirk

Chris Shibutani

Karishma Raghuram

Katherine Wang

Troy Langford

- Alkermes Pharma Ireland Limited (APIL), a subsidiary of Alkermes plc, entered into an **authorized generic product supply agreement** with Amneal Pharmaceuticals LLC on **September 9, 2025**, for a generic version of **VIVITROL®**.  **[1520262_0001193125-25-202307_alks-20250815.htm:1]** 
- Under this agreement, APIL will supply Amneal with a limited quantity, not exceeding approximately **15% of 2024 VIVITROL unit sales**, and will **share Net Profits** from its sales.  **[1520262_0001193125-25-202307_alks-20250815.htm:1]** 
- Alkermes subsidiaries filed **patent infringement lawsuits** against Teva, Apotex, and MSN in August and September 2025, challenging their abbreviated new drug applications (ANDAs) for generic versions of **LYBALVI®**.  **[1520262_0001193125-25-202307_alks-20250815.htm:2]** 
- These lawsuits triggered **30-month stays of FDA approval** for the generic LYBALVI® products, protecting Alkermes' patents which expire between **2032 and 2041**.  **[1520262_0001193125-25-202307_alks-20250815.htm:2]**

Alkermes plc Enters Authorized Generic Agreement for VIVITROL® and Files Patent Infringement Lawsuits for LYBALVI®

Alkermes (ALKS)